AnalystBook Research · Company Intelligence

Alset Inc.

AEINasdaq

Built from Alset Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Alset's revenue collapsed to $4.5M while the net loss widened to $47.4M, making the CEO buy only a small offset.

The read at a glance✓ Audited against SEC data
  • Business mixDiversified real estate and tech holding companyNote
  • RevenueRevenue fell 78.8% to $4.5MWatch
  • ProfitabilityNet loss widened to $47.4MWatch
  • Cash qualityFree cash flow was -$6.1MWatch
  • Balance sheetEquity rose 48.9% to $121.1MOK
  • Insiders1 buy / 2 sells; $42.5K boughtNote
  • AccountingAltman-Z safe; Beneish flag; EQ distressWatch

Business

Alset is a diversified holding company with real estate, financial services, digital transformation technology, biohealth, and consumer-product activities across several countries.

Where the revenue comes from

Fiscal 2025, as Alset Inc. reports it. History and quarterly detail are in the app.

  • Rental$2.8M
  • Other$1.6M

Leadership changes

From Alset Inc.'s own filings, the day they're filed.

  • Anthony S. Chan · Chief Operating Officer · departureeff. 2024-03-10

Latest filings

  • 10-Q · Quarterly report2026-08-14
  • 8-K · Company announcement2026-06-25
  • 10-Q · Quarterly report2026-05-14
  • 8-K · Company announcement2026-05-07
  • 10-K · Annual report2026-03-31
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Alset Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.